10.65
price up icon5.03%   0.51
after-market Handel nachbörslich: 10.84 0.19 +1.78%
loading
Schlusskurs vom Vortag:
$10.14
Offen:
$10.01
24-Stunden-Volumen:
776.18K
Relative Volume:
0.68
Marktkapitalisierung:
$830.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.87M
KGV:
-5.884
EPS:
-1.81
Netto-Cashflow:
$-109.90M
1W Leistung:
+4.11%
1M Leistung:
+25.74%
6M Leistung:
+28.93%
1J Leistung:
+41.62%
1-Tages-Spanne:
Value
$9.96
$11.19
1-Wochen-Bereich:
Value
$9.80
$11.19
52-Wochen-Spanne:
Value
$3.8951
$14.67

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name
Firmenname
Oric Pharmaceuticals Inc
Name
Telefon
(650) 388-5600
Name
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
122
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
ORIC's Discussions on Twitter

Vergleichen Sie ORIC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ORIC
Oric Pharmaceuticals Inc
10.65 830.88M 0 -119.87M -109.90M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-31 Eingeleitet Wells Fargo Overweight
2024-09-06 Eingeleitet Stifel Buy
2024-02-23 Eingeleitet Cantor Fitzgerald Overweight
2023-09-22 Eingeleitet Wedbush Outperform
2023-03-23 Hochstufung H.C. Wainwright Neutral → Buy
2023-03-21 Hochstufung Guggenheim Neutral → Buy
2023-03-16 Hochstufung Oppenheimer Perform → Outperform
2022-07-18 Fortgesetzt Oppenheimer Perform
2022-04-04 Hochstufung Citigroup Neutral → Buy
2022-03-25 Herabstufung H.C. Wainwright Buy → Neutral
2022-03-22 Herabstufung Citigroup Buy → Neutral
2022-03-22 Herabstufung Guggenheim Buy → Neutral
2022-03-22 Herabstufung Oppenheimer Outperform → Perform
2021-07-06 Hochstufung Citigroup Neutral → Buy
2021-01-25 Herabstufung Citigroup Buy → Neutral
2020-08-13 Eingeleitet Robert W. Baird Outperform
2020-08-06 Hochstufung Citigroup Neutral → Buy
2020-08-03 Eingeleitet H.C. Wainwright Buy
2020-05-19 Eingeleitet Citigroup Neutral
2020-05-19 Eingeleitet Guggenheim Buy
2020-05-19 Eingeleitet JP Morgan Overweight
2020-05-19 Eingeleitet Jefferies Buy
Alle ansehen

Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten

pulisher
Jun 18, 2025

Oric Pharmaceuticals (NASDAQ:ORIC) Trading Down 3.4%Here's Why - MarketBeat

Jun 18, 2025
pulisher
Jun 16, 2025

(ORIC) Trading Report - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 15, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down Following Insider Selling - MarketBeat

Jun 15, 2025
pulisher
Jun 14, 2025

Millennium Management LLC Has $223,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Research Analysts Issue Forecasts for ORIC FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 2,976 Shares - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

Oric Pharmaceuticals Elects Directors at Annual Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now? - sharewise

Jun 13, 2025
pulisher
Jun 13, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down After Insider Selling - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Dominic Piscitelli Sells 2,600 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Bank of America Corp DE Acquires 28,570 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Millennium Management LLC Trims Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Brokers Issue Forecasts for ORIC FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Insider Sell: Dominic Piscitelli Sells Shares of ORIC Pharmaceuticals Inc (ORIC) - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of “Buy” from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from Analysts - MarketBeat

Jun 11, 2025
pulisher
Jun 10, 2025

Transcript : ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - MarketScreener

Jun 10, 2025
pulisher
Jun 09, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpStill a Buy? - MarketBeat

Jun 09, 2025
pulisher
Jun 08, 2025

Two Sigma Investments LP Decreases Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat

Jun 08, 2025
pulisher
Jun 08, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Bank of America Corp DE - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up – Here’s What Happened - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ORIC Stock News - GuruFocus

Jun 07, 2025
pulisher
Jun 07, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 7.6%Still a Buy? - MarketBeat

Jun 07, 2025
pulisher
Jun 07, 2025

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - mx.advfn.com

Jun 07, 2025
pulisher
Jun 06, 2025

Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com

Jun 06, 2025
pulisher
Jun 06, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

ORIC Pharmaceuticals Expands Oncology Team with 45,600 Equity Grants for New Clinical Specialists - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

ORIC Pharmaceuticals, Inc. announced that it has received $124.999983 million in funding from a group of investors - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Cantor Fitzgerald Estimates ORIC FY2025 Earnings - MarketBeat

Jun 06, 2025
pulisher
Jun 06, 2025

Two Sigma Investments LP Decreases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 3.5%What's Next? - MarketBeat

Jun 06, 2025
pulisher
Jun 04, 2025

Two Sigma Advisers LP Acquires 8,300 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Viking Invests $125 Million in ORIC Pharmaceuticals PIPE Financing - Global Legal Chronicle

Jun 03, 2025
pulisher
Jun 03, 2025

Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownTime to Sell? - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

H.C. Wainwright maintains buy rating on ORIC Pharmaceuticals stock By Investing.com - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 03, 2025

BNP Paribas Financial Markets Buys New Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Wedbush Reiterates Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat

Jun 03, 2025
pulisher
Jun 02, 2025

Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial - MSN

Jun 02, 2025
pulisher
Jun 02, 2025

Viking in PIPE Investment in ORIC Pharmaceuticals - Cleary Gottlieb

Jun 02, 2025

Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Oric Pharmaceuticals Inc-Aktie (ORIC) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Piscitelli Dominic
Chief Financial Officer
Jun 23 '25
Sale
10.00
1,034
10,344
100,783
You Angie
Director
Jun 20 '25
Buy
9.39
26,597
249,669
26,597
You Angie
Director
Jun 23 '25
Buy
9.43
1,403
13,230
28,000
Piscitelli Dominic
Chief Financial Officer
Jun 12 '25
Sale
10.00
300
3,000
101,817
Piscitelli Dominic
Chief Financial Officer
Jun 11 '25
Sale
10.01
2,976
29,777
102,117
Piscitelli Dominic
Chief Financial Officer
Jun 10 '25
Sale
10.00
324
3,240
105,093
Piscitelli Dominic
Chief Financial Officer
Jun 06 '25
Sale
10.01
2,600
26,021
104,164
Piscitelli Dominic
Chief Financial Officer
Jun 09 '25
Sale
10.00
300
3,000
103,864
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):